论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
头孢菌素所致血小板减少症的风险分层:老年人多维预测模型的开发与验证
Authors Li X, Lei W , Wang M , Xu L
Received 24 April 2025
Accepted for publication 16 June 2025
Published 25 June 2025 Volume 2025:18 Pages 2107—2120
DOI https://doi.org/10.2147/RMHP.S529488
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Kyriakos Souliotis
Xiuyan Li,1,* Wanlin Lei,2,* Maofeng Wang,2 Lili Xu3
1Intensive Care Unit, Affiliated Dongyang Hospital, Wenzhou Medical University, Dongyang, Zhejiang, 322100, People’s Republic of China; 2Department of Biomedical Sciences Laboratory, Affiliated Dongyang Hospital, Wenzhou Medical University, Dongyang, Zhejiang, 322100, People’s Republic of China; 3Department of Obstetrics, Affiliated Dongyang Hospital, Wenzhou Medical University, Dongyang, Zhejiang, 322100, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Maofeng Wang, Email wzmcwmf@wmu.edu.cn Lili Xu, Email xulili41663@163.com
Objective: Third-generation cephalosporins, while widely prescribed, carry underquantified thrombocytopenia risks in older adults. This study aimed to develop and validate a clinical prediction model for cephalosporin-associated thrombocytopenia in hospitalized patients aged over 65 years.
Methods: A retrospective cohort (2019~2023) initially included 45,779 cephalosporin treated patients. After applying exclusion criteria, 12,917 patients were analyzed. Predictors were selected via LASSO regression, with backward elimination multivariate logistic regression constructing a nomogram. Model performance was assessed using AUC, calibration curves, and decision curve analysis (DCA) in training and testing sets.
Results: The final model identified eight predictors: baseline platelet count (PLT), red blood cell count (RBC), presence of tumor, renal insufficiency (RI), liver cirrhosis (LC), meropenem use, use of antifungal drugs (AD), and daily usage frequency (DUF). It demonstrated strong discrimination (training AUC 0.82 [95% CI 0.79– 0.85]; testing AUC 0.80 [0.76– 0.84]) and calibration (Brier score 0.057). DCA confirmed clinical utility across wide risk thresholds.
Conclusion: This nomogram tool enables rapid thrombocytopenia risk assessment in elderly patients receiving cephalosporins. Clinically, it guides antibiotic selection by quantifying comorbidity-drug interactions, and improves toxicity monitoring accuracy in complex geriatric cases with polypharmacy.
Keywords: thrombocytopenia, predictive model, geriatric inpatients, nomogram, third generation cephalosporins